Conflicts of interest A. Menter has received research support and/or lecture honoraria from Abbott Laboratories, Amgen Inc, Centocor Inc. and Wyeth Laboratories. A. Mittal and A. Perlmutter: none declared.
Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians
Article first published online: 22 OCT 2008
© 2008 The Authors. Journal Compilation © 2008 British Association of Dermatologists
British Journal of Dermatology
Volume 160, Issue 1, pages 8–15, January 2009
How to Cite
Perlmutter, A., Mittal, A. and Menter, A. (2009), Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. British Journal of Dermatology, 160: 8–15. doi: 10.1111/j.1365-2133.2008.08891.x
- Issue published online: 15 DEC 2008
- Article first published online: 22 OCT 2008
- Accepted for publication 18 May 2008
- TNF-α antagonist;
Tumour necrosis factor (TNF)-α inhibitors, long used in rheumatology and gastroenterology, have made a significant impact on the therapy of psoriasis and psoriatic arthritis. TNF-α is an important cytokine in normal physiological processes such as the immune response to granulomatous infection. Inhibition of this process by TNF-α inhibitors has been reported to increase the susceptibility of patients to granulomatous infections such as Mycobacterium tuberculosis. Despite the numerous reported cases in the literature and appropriate warnings on the labels for the three currently approved TNF-α inhibitors, current guidelines do not address case-specific issues across the full spectrum of tuberculosis. The probability of developing active tuberculosis has been reported to be as much as seven times higher when recommendations are not followed. We report three cases of tuberculosis induced by TNF-α inhibitors despite a rigorous screening policy in our tertiary care psoriasis centre, and suggest tuberculosis-specific guidelines for clinicians using these agents based on a review of the literature.